Personnel Information

写真a

Akihiro HIRAKAWA


Job title

Professor

Mail Address

a-hirakawa.crc@tmd.ac.jp

Field Introduction URL

http://tmdu-biostat-datascience.com/

Graduate School 【 display / non-display

  • Tokyo University of Science, Graduate School, Division of Engineering, Doctor's Course, Completed

Campus Career 【 display / non-display

  • 2020.04
    -
    2021.09
    Tokyo Medical and Dental University, Medical Hospital, Central Clinical Facilities, Clinical Research Center, Professor
  • 2020.11
    -
    Now
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Division of Public Health, Department of Clinical Biostatistics, Professor
  • 2021.10
    -
    2022.07
    Tokyo Medical and Dental University, Tokyo Medical and Dental University, Division of Clinical Management, Clinical Research Center, Professor
  • 2022.08
    -
    Now
    Tokyo Medical and Dental University, Tokyo Medical and Dental University, Division of Clinical Management, Clinical Research Center, Professor

External Career 【 display / non-display

  • 2011.04
    -
    2012.03
    , Assistant Professor
  • 2017.04
    -
    2020.03
    , Project Associate Professor

Academic Activity 【 display / non-display

  • 2020.04
    -
    Now
    Japanese Journal of Clinical Oncology Reviewer Board Member
 

Published Papers & Misc 【 display / non-display

  1. Oda G, Nakagawa T, Mori H, Onishi I, Fujioka T, Mori M, Kubota K, Hanazawa R, Hirakawa A, Ishikawa T, Okamoto K, Uetake H. Factors predicting upstaging from clinical N0 to pN2a/N3a in breast cancer patients. World Journal of Clinical Oncology. 2022.09; 13 (9): 748-757. ( DOI )

  2. Takahashi Y, Yamamoto T, Oyama J, Sugihara G, Shirai Y, Tao S, Takigawa M, Sato H, Sasaki M, Hirakawa A, Takahashi H, Goya M, Sasano T. Increase in Cerebral Blood Flow after Catheter Ablation of Atrial Fibrillation JACC. 2022.09;

  3. Sakaki K, Yoshii T, Arai Y, Torigoe I, Tomori M, Onuma H, Ogawa T, Hirakawa A, Sakai K, Okawa A. Effectiveness of Lumbosacral Orthosis after Discectomy for Lumbar Disc Herniation: A Prospective Comparative Study. Spine. 2022.09; ( PubMed, DOI )

  4. Murata K, Takahashi Y, Inaba O, Nitta J, Kobori A, Sakamoto Y, Nagata Y, Tanimoto K, Matsuo S, Yamane T, Morita N, Satomi K, Sato H, Hanazawa R, Hirakawa A, Goya M, Sasano T. Efficacy of Left Atrial Posterior Wall Isolation Guided by Lesion Size Prediction Module for Non-paroxysmal Atrial Fibrillation. EP Europace, euac079. 2022.07; ( DOI )

  5. Nakayama K, Shachar S, Finn EH, Sato H, Hirakawa A, Misteli T. Large-scale mapping of positional changes of hypoxia-responsive genes upon activation. Molecular biology of the cell. 2022.07; 33 (8): ar72. ( PubMed, DOI )

  6. Hirakawa A, Sato H, Hanazawa R, Suzuki K, Japanese Alzheimer's Disease Neuroimaging Initiative.. Estimating the longitudinal trajectory of cognitive function measurement using short-term data with different disease stages: Application in Alzheimer's disease. Statistics in medicine. 2022.06; 41 (21): 4200-4214. ( PubMed, DOI )

  7. Matsuyama N, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R, Katayama A, Ando M, Mizuno M, Hirakawa A, Hayakawa M, Sato Y. Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial. BMJ OPEN. 2022.04; 12 (4): ( DOI )

  8. Kotani T, Imai K, Ushida T, Moriyama Y, Nakano-Kobayashi T, Osuka S, Tsuda H, Sumigama S, Yamamoto E, Kinoshita F, Hirakawa A, Iwase A, Kikkawa F, Kajiyama H. Pregnancy Outcomes in Women with Thyroid Diseases. JMA journal. 2022.04; 5 (2): 216-223. ( PubMed, DOI )

  9. Takino K, Kameshima M, Asai C, Kawamura I, Tomita S, Sato H, Hirakawa A, Yamada S. Neuromuscular electrical stimulation mitigates muscle weakness in elderly diabetic patients after cardiovascular surgery Annals of Physical and Rehabilitation Medicine. 2022.03; ( DOI )

  10. Takino K, Kameshima M, Asai C, Kawamura I, Tomita S, Sato H, Hirakawa A, Yamada S. Neuromuscular electrical stimulation after cardiovascular surgery mitigates muscle weakness in older individuals with diabetes. Annals of physical and rehabilitation medicine. 2022.03; 101659. ( PubMed, DOI )

  11. Hirakawa A, Sato H, Igeta M, Fujikawa K, Daimon T, Teramukai S. Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan. Pharmaceutical statistics. 2022.01; 21 (3): 691-695. ( PubMed, DOI )

  12. Inose H, Kato T, Sasaki M, Matsukura Y, Hirai T, Yoshii T, Kawabata S, Hirakawa A, Okawa A. Comparison of decompression, decompression plus fusion, and decompression plus stabilization: a long-term follow-up of a prospective, randomized study. The spine journal : official journal of the North American Spine Society. 2021.12; 22 (5): 747-755. ( PubMed, DOI )

  13. Oba S, Hosoya T, Amamiya M, Mitsumura T, Kawata D, Sasaki H, Kamiya M, Yamamoto A, Ando T, Shimada S, Shirai T, Okamoto T, Tateishi T, Endo A, Aiboshi J, Nosaka N, Yamanouchi H, Ugawa T, Nagaoka E, Oi K, Tao S, Maejima Y, Tanaka Y, Tanimoto K, Takeuchi H, Tohda S, Hirakawa A, Sasano T, Arai H, Otomo Y, Miyazaki Y, Yasuda S. Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. Frontiers in Cardiovascular Medicine. 2021.11; ( DOI )

  14. Oba S, Hosoya T, Amamiya M, Mitsumura T, Kawata D, Sasaki H, Kamiya M, Yamamoto A, Ando T, Shimada S, Shirai T, Okamoto T, Tateishi T, Endo A, Aiboshi J, Nosaka N, Yamanouchi H, Ugawa T, Nagaoka E, Oi K, Tao S, Maejima Y, Tanaka Y, Tanimoto K, Takeuchi H, Tohda S, Hirakawa A, Sasano T, Arai H, Otomo Y, Miyazaki Y, Yasuda S. Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan Frontiers in Cardiovascular Medicine. 2021.11;

  15. Noda-Narita S, Kawachi A, Okuyama A, Sadachi R, Hirakawa A, Goto Y, Fujiwara Y, Higashi T, Yonemori K. First-line treatment for lung cancer among Japanese older patients: a real-world analysis of hospital-based cancer registry data PLOS ONE. 2021.09; 16 (9): ( DOI )

  16. Omori H, Hara M, Sobue Y, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Ota H, Okubo M, Hirakawa A, Suzuki T, Kondo T, Leipsic J, NØrgaard B L, Matsuo H.. Determination of the Optimal Measurement Point for Fractional Flow Reserve Derived From CTA Using Pressure Wire Assessment as Reference American Journal of Roentgenology. 2021.06; 216 (6): 1492-1499.

  17. Takahashi Y, Nitta J, Kobori A, Sakamoto Y, Nagata Y, Tanimoto K, Matsuo S, Yamane T, Morita N, Satomi K, Inaba O, Murata K, Sasaki Y, Yoshimoto D, Kaneko M, Tanimoto Y, Isogai R, Yamashita S, Sato H, Hanazawa R, Hirakawa A, Goya M, Sasano T.. Alcohol Consumption Reduction and Clinical Outcomes of Catheter Ablation for Atrial Fibrillation Circulation:Arrhythmia and electrophysiology. 2021.06; 14 (6):

  18. Sugimoto T, Sakurai T, Akatsu H, Doi T, Fujiwara Y, Hirakara A, Kinoshita F, Kuzuya M, Lee S, Matsuo K, Michikawa M, Ogawa S, Otsuka R, Sato K, Shimada H, Suzuki H, Takechi H, Takeda S, Umegaki H, Wakayama S, Arai H, J-MINT investigators. The Japan-Multimodal Intervention Trial for Prevention of Dementia (J-MINT): The Study Protocol for an 18-Month, Multicenter, Randomized, Controlled Trial The Journal of Prevention of Alzheimer's Disease. 2021.06;

  19. Ezaki A, Hirakawa A, Hanaoka H, Uyama Y. . Factors Influencing Classifications of Safety Specifications in a Risk Management Plan for Antineoplastic Agents Approved in Japan: A Review and Descriptive Analysis Therapeutic innovation & regulatory science. 2021.06;

  20. Mori M, Watabe S, Taguchi T, Hasegawa H, Ishige M, Tanuma N, Hirakawa A, Koike R, Kusuda S. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection. BMC pediatrics. 2021.03; 21 (1): 106. ( PubMed, DOI )

  21. Mori M, Watabe S, Taguchi T, Hasegawa H, Ishige M, Tanuma N, Hirakawa A, Koike R, Kusuda S.. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection BMC Pediatrics. 2021.03; 21 (1):

  22. Yamada S, Hashizume A, Hijikata Y,Ito D, Kishimoto Y, Iida M, Koike H, Hirakawa A, Katsuno M.. Ratio of urinary N-terminal titin fragment to urinary creatinine is a novel biomarker for amyotrophic lateral sclerosis Journal of Neurology,Neurosurgery & Psyychiatry. 2021.03;

  23. Ota H, Omori H, Kawasaki M, Hirakawa A, Matsuo H. Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study. European heart journal cardiovascular Imaging. 2021.02; 23 (2): 217-228. ( PubMed, DOI )

  24. Ikenouchi T, Inaba O, Takamiya T, Inamura Y, Sato A, Matsumura Y, Sato H, Hirakawa A, Takahashi Y, Goya M, Sasano T, Nitta J. The impact of left atrium size on selection of the pulmonary vein isolation method for atrial fibrillation: Cryoballoon or radiofrequency catheter ablation. American heart journal. 2021.01; 231 82-92. ( PubMed, DOI )

  25. Sano T, Kato M, Sassa N, Sadachi R, Hirakawa A, Kamihira O, Hirabayashi T, Nishikimi T, Katsuno S, Kimura T, Hattori R, Gotoh M, Tsuzuki T. pT3 subclassification of renal pelvic cancer considering the tumor location improves the patients' prognostic accuracy. Virchows Archiv : an international journal of pathology. 2021.01; 478 (6): 1089-1097. ( PubMed, DOI )

  26. Kato M, Hirakawa A, Sato H, Hanazawa R, Naito Y, Tochigi K, Sano T, Ishida S, Funahashi Y, Fujita T, Matsukawa Y, Hattori R, Tsuzuki T. Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate. International journal of clinical oncology. 2021.01; 26 (4): 764-769. ( PubMed, DOI )

  27. Kawase Y, Omori H, Tanigaki T, Hirakawa A, Hirata T, Ota H, Kikuchi J, Sobue Y, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Matsuo H. In vivo validation of resting full-cycle ratio and diastolic pressure ratio: simultaneous measurement with instantaneous wave-free ratio. Cardiovascular intervention and therapeutics. 2021.01; 36 (1): 74-80. ( PubMed, DOI )

  28. Kawatsu Y, Tsuchida J, Ando S, Hirakawa A, Sozu T. Sample size determination in phase I oncology trials based on selection probability of the maximum tolerated dose. Japanese Journal of Biometrics. 2021; 42 (1): 55-64. ( DOI )

  29. Okuma HS, Yonemori K, Kojima Y, Tanioka M, Sudo K, Noguchi E, Hijioka S, Wakakuwa K, Kato K, Hirakawa A, Kuchiba A, Kubo T, Ichikawa H, Yoshida A, Yatabe Y, Nakamura K, Mano H, Yamamoto N, Fujiwara Y. Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers. Frontiers in oncology. 2021; 11 732525. ( PubMed, DOI )

  30. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Naito Y, Tochigi K, Sano T, Ishida S, Funahashi Y, Fujita T, Matsukawa Y, Hattori R, Tsuzuki T. Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer. International journal of clinical oncology. 2020.12; 25 (12): 2130-2137. ( PubMed, DOI )

  31. Kaneko S, Hirakawa A. Assessment of Overall Treatment Effect in the Presence of Inconsistent Regional Effects in Multiregional Clinical Trials Statistics in Biopharmaceutical Research. 2020.12;

  32. Kuwatsuka Y, Atsuta Y, Hirakawa A, Uchida N, Inamoto Y, Najima Y, Ikegame K, Eto T, Ozawa Y, Ichinohe T, Inoue M, Kimura T, Okamoto S, Miyamura K, Fukuda T. Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection. International journal of hematology. 2020.12; 112 (6): 841-850. ( PubMed, DOI )

  33. Goto T, Murata M, Nishida T, Terakura S, Kamoshita S, Ishikawa Y, Ushijima Y, Adachi Y, Suzuki S, Kato K, Hirakawa A, Nishiwaki S, Nishio N, Takahashi Y, Kodera Y, Matsushita T, Kiyoi H. Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation. Stem cells translational medicine. 2020.12; 10 (4): 542-553. ( PubMed, DOI )

  34. Asano J, Hirakawa A. A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations. Pharmaceutical statistics. 2020.11; 19 (6): 975-1000. ( PubMed, DOI )

  35. Yokoi K, Hattori M, Satake Y, Tanaka Y, Sato M, Hashizume A, Hori A, Kawashima M, Hirakawa A, Watanabe H, Katsuno M. Longitudinal analysis of premotor anthropometric and serological markers of Parkinson's disease. Scientific reports. 2020.11; 10 (1): 20524. ( PubMed, DOI )

  36. Omori H, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Kikuchi J, Ota H, Sobue Y, Miyake T, Kawamura I, Okubo M, Kamiya H, Hirakawa A, Kawasaki M, Nakagawa M, Tsuchiya K, Suzuki Y, Ito T, Terashima M, Kondo T, Suzuki T, Escaned J, Matsuo H. Comparisons of Nonhyperemic Pressure Ratios: Predicting Functional Results of Coronary Revascularization Using Longitudinal Vessel Interrogation. JACC. Cardiovascular interventions. 2020.11; 13 (22): 2688-2698. ( PubMed, DOI )

  37. Saito T, Hatta Y, Hayakawa F, Takahashi T, Hagihara M, Iida H, Minauchi K, Yamazaki E, Sugiura I, Murayama T, Sakura T, Mori N, Imai K, Yahagi Y, Atsuta Y, Saito AM, Hirakawa A, Kiyoi H, Matsumura I, Miyazaki Y, Japan Adult Leukemia Study Group.. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group. International journal of hematology. 2020.11; 113 (3): 395-403. ( PubMed, DOI )

  38. Kato T, Motoji Y, Tamaki M, Inagaki M, Tsunekawa T, Hirakawa A, Okawa Y, Tomita S. Clinical benefits of fast-track rehabilitation program for patients with uncomplicated type B acute aortic dissection. General thoracic and cardiovascular surgery. 2020.11; 68 (11): 1234-1239. ( PubMed, DOI )

  39. Gotoh M, Shimizu S, Yamamoto T, Ishizuka O, Yamanishi T, Mizokami A, Narimoto K, Toriyama K, Kamei Y, Nakayama S, Kuwatsuka Y, Mizuno M, Hirakawa A. Regenerative treatment for male stress urinary incontinence by periurethral injection of adipose-derived regenerative cells: Outcome of the ADRESU study. International journal of urology : official journal of the Japanese Urological Association. 2020.10; 27 (10): 859-865. ( PubMed, DOI )

  40. Omori H, Hara M, Sobue Y, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Ota H, Okubo M, Hirakawa A, Suzuki T, Kondo T, Leipsic J, Nørgaard BL, Matsuo H. Determination of the Optimal Measurement Point for Fractional Flow Reserve Derived from CT Angiography Using Pressure Wire Assessment as Reference. AJR. American journal of roentgenology. 2020.09; 216 (6): 1492-1499. ( PubMed, DOI )

  41. Okuma HS, Yonemori K, Narita SN, Sukigara T, Hirakawa A, Shimizu T, Shibata T, Kawai A, Yamamoto N, Nakamura K, Nishida T, Fujiwara Y. MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial. Clinical pharmacology and therapeutics. 2020.09; 108 (3): 596-605. ( PubMed, DOI )

  42. Takahashi K, Ishibashi E, Kubo T, Harada Y, Hayashi H, Kano M, Shimizu Y, Shirota H, Mori Y, Muto M, Ishioka C, Dosaka-Akita H, Matsubara H, Nishihara H, Sueoka-Aragane N, Toyooka S, Hirakawa A, Tateishi U, Miyake S, Ikeda S. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial). Medicine. 2020.08; 99 (32): e21457. ( PubMed, DOI )

  43. Nishida Y, Hamada S, Kawai A, Kunisada T, Ogose A, Matsumoto Y, Ae K, Toguchida J, Ozaki T, Hirakawa A, Motoi T, Sakai T, Kobayashi E, Gokita T, Okamoto T, Matsunobu T, Shimizu K, Koike H. Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: A multicenter study in Japan. Cancer science. 2020.08; 111 (8): 2935-2942. ( PubMed, DOI )

  44. Ushida T, Kotani T, Hayakawa M, Hirakawa A, Sadachi R, Nakamura N, Moriyama Y, Imai K, Nakano-Kobayashi T, Kikkawa F. Antenatal corticosteroids and preterm offspring outcomes in hypertensive disorders of pregnancy: A Japanese cohort study. Scientific reports. 2020.06; 10 (1): 9312. ( PubMed, DOI )

  45. Majima S, Wakahara K, Nishio T, Nishio N, Teranishi M, Iwano S, Hirakawa A, Hashimoto N, Sone M, Hasegawa Y.. Bronchial wall thickening is associated with severity of chronic rhinosinusitis. Respiratory Medicine.. 2020.05;

  46. Kaneko S, Hirakawa A, Kakurai Y, Hamada C.. A dose-finding approach for genomic patterns in phase I trials. Journal of Biopharmaceutical Statistics. 2020.04;

  47. Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, Ushijima T, Tamura K.. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. Breast Cancer Research and Treatment. 2020.04; 181 (2): 323-329.

  48. Matsumoto T, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, Hirakawa A, Soen S. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA) Journal of Bone and Mineral Metabolism. 2020.03;

  49. Nishizawa M, Onodera O, Hirakawa A, Shimizu Y, Yamada M; Rovatirelin Study Group. Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials. Journal of Neurology, Neurosurgery & Psychiatry,. 2020.03; 91 (3): 254-262.

  50. 小山 隆文, 清水 俊雄, 米盛 勧, 小島 勇貴, 松井 直子, 大熊 ひとみ, 野口 瑛美, 須藤 一起, 平川 晃弘, 沖田 南都子, 都祭 紗和子, 鋤柄 多美恵, 中村 健一, 田村 研治, 山本 昇, 藤原 康弘. MDM2阻害剤を用いた内膜肉腫対象医師主導治験 日本心臓血管外科学会学術総会抄録集. 2020.03; 50回 P23-3. ( ichushi )

  51. Hattori M, Tsuboi T, Yokoi K, Tanaka Y, Sato M, Suzuki K, Arahata Y, Hori A, Kawashima M, Hirakawa A, Washimi Y, Watanabe H, Katsuno M.. Subjects at risk of Parkinson’s disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study. Journal of Neurology. 2020.02; 267 (5): 1516-1526.

  52. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Ishida R, Kamihira O, Sano T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Hattori R, Gotoh M, Tsuzuki T. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients. The Prostate. 2020.02; 80 (3): 284-290.

  53. Okuma HS, Yonemori K, Narita SN, Sukigara T, Hirakawa A, Shimizu T, Shibata T, Kawai A, Yamamoto N, Nakamura K, Nishida T, Fujiwara Y. . MASTER KEY Project: Powering Clinical Development for Rare Cancers through a Platform Trial. Clinical Pharmacology & Therapeutics. 2020.02;

  54. Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita T, Shibui S, Fujiwara Y. Disruption of the blood brain barrier by brain metastases of triple negative and basal-type breast cancer but not HER2/neu-positive breast cancer Cancer. 2020.01; 116 (2): 302-308.

  55. Ushida T,Kotani T, Sadachi R, Hirakawa A, Hayakawa M, Moriyama Y, Imai K, Nakano-Kobayashi T, Kikkawa F, for the Neonatal Research Network of Japan. Antenatal Corticosteroids and Outcomes in Preterm Twins. Obstetrics and Gynecology. 2020.01; 135 (6): 1387-1397.

  56. Sakakibara S, Hashimoto R, Katayama T, Kenjyo M, Yokokawa Y, Saito Y, Hirakawa A, Ito M, Nakamura T, Hara K, Hashizume A, Aiba I, Inukai A, Katsuno M. Longitudinal change of DAT SPECT in Parkinson’s disease and multiple system atrophy. Journal of Parkinson's Disease . 2020.01; 10 (1): 123-130.

  57. Soen S, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano T, Hagino H, Hirakawa A, Matsumoto T. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. Journal of Bone and Mineral Metabolism. 2020.01;

  58. Kitase Y, Sato Y, Arai S, Onoda A, Ueda K, Go S, Mimatsu H, Jabary M, Suzuki T, Ito M, Saito A, Hirakawa A, Mukai T, Nagamura-Inoue T, Takahashi Y, Tsuji M, Hayakawa M. Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells. Frontiers in cellular neuroscience. 2020; 14 212. ( PubMed, DOI )

  59. Suzuki K, Hirakawa A, Ihara R, Iwata A, Ishii K, Ikeuchi T, Sun CK, Donohue M, Iwatsubo T, Alzheimer's Disease Neuroimaging Initiative, Japanese Alzheimer's Disease Neuroimaging Initiative.. Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). 2020; 6 (1): e12007. ( PubMed, DOI )

  60. Hirakawa A, Tanaka Y, Kaneko S. . Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials. Contemporary Clinical Trial Communications . 2019.12; 16 100489.

  61. Hirakawa A, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, Okuma SH, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Takebe N. . A comparative study of longitudinal toxicities of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, and cancer vaccines. Clinical Pharmacology & Therapeutics. 2019.10; 106 (4): 803-809.

  62. Ito D, Hashizume A, Hijikata Y, Yamada S, Iguchi Y, Iida M, Kishimoto Y, Moriyoshi H, Hirakawa A, Katsuno M. Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. Journal of Neurology. 2019.08; 266 (12): 2952-2961.

  63. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Ishida R, Sano T, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T.. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance. Prostate. 2019.07; 79 (10): 1065-1070.

  64. Taniguchi A, Kawada JI, Go K, Fujishiro N, Hosokawa Y, Maki Y, Sugiyama Y, Suzuki M, Tsuji T, Hoshino S, Muramatsu H, Kidokoro H, Kinoshita F, Hirakawa A, Takahashi Y, Sato Y, Natsume J, Nagoya Collaborative Clinical Research Team.. Comparison of Clinical Characteristics of Human Metapneumovirus and Respiratory Syncytial Virus Infections in Hospitalized Young Children. Japanese journal of infectious diseases. 2019.07; 72 (4): 237-242. ( PubMed, DOI )

  65. Yokoyama T, Miyahara R, Funasaka K, Furukawa K, Yamamura T, Ohno E, Nakamura M, Kawashima H, Watanabe O, Hirooka Y, Hirakawa A, Goto H.. The utility of ultrathin endoscopy with flexible spectral imaging color enhancement for early gastric cancer. Nagoya Journal of Medical Science. 2019.05; 81 (2): 241-248.

  66. Maeda T, Sato Y, Hirakawa A, Nakatochi M, Kinoshita F, Suzuki T, Ichimura S, Ito R, Kudo R, Suzuki M, Hoshino S, Sugiyama Y, Muramatsu H, Kidokoro H, Kawada JI, Takahashi Y. Design of a prospective multicenter randomized controlled trial evaluating the effects of gastric lavage on coffee-ground emesis in neonates: study protocol. Nagoya Journal of Medical Science. 2019.05; 81 (2): 227-232.

  67. Takano N, Yamada S, Hirakawa A, Yokoyama Y, Kawashima H, Maeda O, Okada T, Ohno E, Yamaguchi J, Ishikawa T, Sonohara F, Suenaga M, Takami H, Hayashi M, Niwa Y, Hirooka Y, Ito Y, Naganawa S, Ando Y, Nagino M, Goto H, Fujii T, Kodera Y. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study Nagoya Journal of Medical Science. 2019.05; 81 (2): 233-239.

  68. Yoshimi A, Yamada S, Kunimoto S, Aleksic B, Hirakawa A, Ohashi M, Matsumoto Y, Hada K, Itoh N, Arioka Y, Kimura H, Kushima I, Nakamura Y, Shiino T, Mori D, Tanaka S, Hamada S, Noda Y, Nagai T, Yamada K, Ozaki N. Author Correction: Proteomic analysis of lymphoblastoid cell lines from schizophrenic patients. Translational psychiatry. 2019.05; 9 (1): 146. ( PubMed, DOI )

  69. Ikenaka K, Atsuta N, Maeda Y, Hotta Y, Nakamura R, Kawai K, Yokoi D, Hirakawa A, Taniguchi A, Morita M, Mizoguchi K, Mochizuki H, Kimura K, Katsuno M, Sobue G.. Increase of arginine dimethylation correlates with the progression and prognosis of ALS Neurology. 2019.04; 92 (16): e1868-e1877.

  70. Yoshimi A, Yamada S, Kunimoto S, Aleksic B, Hirakawa A, Ohashi M, Matsumoto Y, Hada K, Itoh N, Arioka Y, Kimura H, Kushima I, Nakamura Y, Shiino T, Mori D, Tanaka S, Hamada S, Noda Y, Nagai T, Yamada K, Ozaki N. Proteomic analysis of lymphoblastoid cell lines from schizophrenic patients. Translational Psychiatry. 2019.04; 9 126.

  71. Shimizu S, Tsuchiya S, Hirakawa A, Kato K, Ando M, Mizuno M, Osugi M, Okabe K, Katagiri W, Hibi H.. Design of a Randomized Controlled Clinical Study of tissue-engineered osteogenic materials using bone marrow-derived mesenchymal cells for Maxillomandibular bone defects in Japan: the TEOM study protocol. BMC Oral Health,. 2019.04; 19 (1): 69.

  72. Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y.. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. European Journal of Cancer. 2019.03; 109 84-91.

  73. Hashizume A, Katsuno M, Suzuki K, Banno H, Takeuchi Y, Kawashima M, Suga N, Mano T, Araki A, Hijikata Y, Hirakawa A, Sobue G; JASMITT study group. Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials. Journal of Neurology. 2019.03; 266 (5): 1211-1221.

  74. Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Yamazaki N, Fujimoto M, Tamura K, Fujiwara Y.. Anti-cancer agent-induced life-threatening skin toxicities: A database study of spontaneous reporting data. The Oncologist. 2019.02; 24 (2): 266-272.

  75. Kakurai Y, Kaneko S, Hamada C, Hirakawa A (corresponding author. Dose individualization and variable selection using Bayesian Lasso in early phase dose-finding trials. Applied Statistics. 2019.02; 68 (2): 445-460.

  76. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Ishida R, Kamihira O, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T. Integrating Tertiary Gleason Pattern 5 into the ISUP Grading System Improves Prediction of Biochemical Recurrence in Radical Prostatectomy Patients. Modern Pathology. 2019.01; 32 (1): 122-127.

  77. Kada A, Hirakawa A (co-first author), Kinoshita F, Kobayashi Y, Hatakeyama T, Kobayashi D, Nishiyama C, Iwami T.. Sample size estimation and re-estimation of cluster randomized controlled trials for real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests. Contemporary Clinical Trials Communications . 2019.01; 14 100316.

  78. Ogawa C, Sato Y, Suzuki C, Mano A, Tashiro A, Niwa T, Hamazaki S, Tanahashi Y, Suzumura M, Hayano S, Hayakawa M, Tsuji T, Hoshino S, Sugiyama Y, Kidokoro H, Kawada JI, Muramatsu H, Hirakawa A, Ando M, Natsume J, Kojima S. Correction: Treatment with silver nitrate versus topical steroid treatment for umbilical granuloma: A non-inferiority randomized control trial. PloS one. 2019; 14 (6): e0218205. ( PubMed, DOI )

  79. Sato Y, Ueda K, Kondo T, Hattori T, Mikrogeorgiou A, Sugiyama Y, Suzuki T, Yamamoto M, Hirata H, Hirakawa A, Nakanishi K, Tsuji M, Hayakawa M. Administration of Bone Marrow-Derived Mononuclear Cells Contributed to the Reduction of Hypoxic-Ischemic Brain Injury in Neonatal Rats. Frontiers in Neurology. 2018.11; 9 987.

  80. Saji N, Sakurai T, Ito K, Tomimoto H, Kitagawa K, Miwa K, Tanaka Y, Kozaki K, Kario K, Eto M, Suzuki K, Shimizu A, Niida S, Hirakawa A, Toba K; Strawberry study investigators. Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study). BMJ Open. 2018.11; 8 (11): e021759.

  81. 川村 一太, 梶浦 涼, 平川 晃弘, 近藤 武, 鈴木 孝彦, 松尾 仁司. D-SPECTによる安静Tc/負荷Tl 2核種同時撮像プロトコールの診断能 核医学. 2018.11; 55 (Suppl.): S175. ( ichushi )

  82. Kawamura I, Kajiura R, Motoji Y, Okamoto S, Tanigaki T, Omori H, Hirata T, Kikuchi J, Ota H, Sobue Y, Miyake T, Tsunekawa T, Kato T, Kawase Y, Okubo M, Kamiya H, Tsuchiya K, Tomita S, Hirakawa A, Kondo T, Suzuki T, Matsuo H. Diagnostic Performance of the Simultaneous Acquisition Rest 99mTc-Tetrofosmin/Stress 201Tl Dual Isotope Protocol with a Semiconductor Camera: Comparison with the Rest-Stress 99mTc-Tetrofosmin Protocol. Circulation Journal. 2018.10; 82 (11): 2837-2844.

  83. Sakamoto Y, Okamoto S, Shimizu K, Araki Y, Hirakawa A, Wakabayashi T.. Comparative Prospective Study of Microvascular Anastomosis Training by Self-Learning or with Expert Instruction. World Neurosurgery. 2018.10; 118 e818-e824.

  84. Yamada S, Hashizume A, Hijikata Y, Inagaki T, Ito D, Kinoshita F, Nakatochi M, Kobayashi Y, Hirakawa A, Nakamura T, Katsuno M.. Study protocol for the MEXiletine hydrochloride administration trial: A placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS). BMJ Open. 2018.09; 8 (9): e023041.

  85. Tsuda H, Kotani T, Nakano T, Imai K, Ushida T, Hirakawa A, Kinoshita F, Takahashi Y, Iwagaki S, Kikkawa F. . The rate of neonatal respiratory distress syndrome/transient tachypnea in the newborn and the amniotic lamellar body count in twin pregnancies compared with singleton pregnancies. Clinica Chimica Acta. 2018.09; 484 293-297.

  86. Tsuda H, Kotani T, Nakano T, Imai K, Ushida T, Hirakawa A, Kinoshita F, Takahashi Y, Iwagaki S, Kikkawa F. The impact of fertility treatment on the neonatal respiratory outcomes and amniotic lamellar body counts in twin pregnancies. Clinica Chimica Acta. 2018.09; 484 192-196.

  87. Yamada S, Fujii T, Hirakawa A, Takami H, Suenaga M, Hayashi M, Niwa Y, Hattori N, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y. Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms. Pancreas. 2018.09; 47 (8): 974-979. ( PubMed, DOI )

  88. Hirakawa A, Hatakeyama T, Kobayashi D, Nishiyama C, Kada A, Kiguchi T, Kawamura T, Iwami T. Real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests: a study protocol for a cluster parallel-group randomized controlled trial. Trials. 2018.09; 19 (1): 510. ( PubMed, DOI )

  89. Hirakawa A, Asano J, Sato H, Teramukai S.. Master protocol trials in oncology: Review and new trial designs. Contemporary Clinical Trial Communication. 2018.08; 12 1-8.

  90. Kawase Y, Tanigaki T, Hirakawa A, Omori H, Hirata T, Okamoto S, Ota H, Kikuchi J, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Matsuo H. Frequency of a large drift caused by pressure wire using optical fibers Cardiovascular Intervention and Therapeutics. 2018.07; 33 (3): 270-276.

  91. Kawase Y, Kawasaki M, Kikuchi J, Hirata T, Okamoto S, Tanigaki T, Omori H, Ota H, Okubo M, Kamiya H, Hirakawa A, Matsuo H. Residual pressure gradient across the implanted stent: An important factor of post-PCI physiological results. Journal of Cardiology. 2018.05; 71 (5): 458-463.

  92. Hyodo R, Sato Y, Ito M, Sugiyama Y, Ogawa C, Kawai H, Nakane T, Saito A, Hirakawa A, Kidokoro H, Natsume J, Hayakawa M. Magnetic resonance spectroscopy in preterm infants: association with neurodevelopmental outcomes Archives of Disease in Childhood. 2018.05; 103 (3): f238-f244.

  93. Hirakawa A, Nishikawa T, Yonemori K, Shibata T, Nakamura K, Ando M, Ueda T, Ozaki T, Tamura K, Kawai A, Fujiwara Y.. Utility of Bayesian single-arm design in new drug application for rare cancers in Japan: a case study of phase 2 trial for sarcoma. Therapeutic Innovation & Regulatory Science. 2018.05; 52 (3): 334-338.

  94. Kimura K, Itoh Y, Okada T, Kubota S, Kawamura M, Nakahara R, Oie Y, Kozai Y, Takase Y, Tsuzuki H, Nishio N, Hiramatsu M, Fujimoto Y, Mizutani T, Hirakawa A, Naganawa S. Study Protocol: Prospective Study of Concurrent Chemoradiotherapy with S-1 and Hypofractionated Radiotherapy for Outpatients with Early Glottic Squamous Cell Carcinomas Asian Pacific journal of cancer prevention : APJCP. 2018.05; 19 (5): 1195-1199. ( PubMed, DOI )

  95. Goto T, Murata M, Terakura S, Nishida T, Adachi Y, Ushijima Y, Shimada K, Ishikawa Y, Hayakawa F, Nishio N, Nishiwaki S, Hirakawa A, Kato K, Takahashi Y, Kiyoi H. Phase I study of cord blood transplantation with intra-bone marrow injection of mesenchymal stem cells: A clinical study protocol. Medicine. 2018.04; 97 (17): e0449.

  96. Ozeki N, Fukui T, Kawaguchi K, Nakamura S, Hakiri S, Kato T, Hirakawa A, Yokoi K. A survival analysis using physique-adjusted tumor size of non-small cell lung cancer International Journal of Clinical Oncology. 2018.04; 23 (2): 266-274.

  97. Hijikata Y, Hashizume A, Yamada S, Inagaki T, Ito D, Hirakawa A, Suzuki K, Atsuta N, Tsuboi T, Hattori M, Hori A, Banno H, Sobue G, Katsuno M. Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy Neurology. 2018.04; 90 (17): e1501-e1509.

  98. Ohsawa Y, Hagiwara H, Nishimatsu SI, Hirakawa A, Kamimura N, Ohtsubo H, Fukai Y, Murakami T, Koga Y, Goto YI, Ohta S, Sunada Y; KN01 Study Group. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. Journal of Neurology, Neurosurgery, and Psychiatry. 2018.04; 90 (5): 529-536.

  99. Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, Inagaki T, Ito D, Hirakawa A, Kinoshita F, Gosho M, Sobue G. Treatment with Creatine Monohydrate in Spinal and Bulbar Muscular Atrophy: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial. JMIR research protocols. 2018.03; 7 (3): e69. ( PubMed, DOI )

  100. Imai K, Kotani T, Nakano T, Ushida T, Hirakawa A, Kikkawa F.. Maternal protein S activity is associated with massive hemorrhage during Caesarean section: Retrospective case-control study. The Journal of Maternal-Fetal & Neonatal Medicine,. 2018.02; 32 (16): 2633-2637.

  101. Ogawa C, Kidokoro H, Fukasawa T, Yamamoto H, Ishihara N, Ito Y, Sakaguchi Y, Okai Y, Ohno A, Nakata T, Azuma Y, Hattori A, Kubota T, Tsuji T, Hirakawa A, Kawai H, Natsume J. Cytotoxic edema at onset in West syndrome of unknown etiology: a longitudinal DTI study Epilepsia. 2018.02; 59 (2): 440-448.

  102. Ogawa C, Sato Y, Suzuki C, Mano A, Tashiro A, Niwa T, Hamazaki S, Tanahashi Y, Suzumura M, Hayano S, Hayakawa M, Tsuji T, Hoshino S, Sugiyama Y, Kidokoro H, Kawada JI, Muramatsu H, Hirakawa A, Ando M, Natsume J, Kojima S. Treatment with silver nitrate versus topical steroid treatment for umbilical granuloma: a non-inferiority randomized control trial. PLOS ONE. 2018.02; 13 (2): e0192688.

  103. Shimamura F, Hamada C, Matsui S, Hirakawa A(corresponding author). Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials. Journal of Biopharmaceutical Statistics. 2018.02; 28 (6): 1025-1037.

  104. Kato M, Kimura K, Hirakawa A, Kobayashi Y, Ishida R, Kamihira O, Majima T, Funahashi Y1, Sassa N, Matsukawa Y, Hattori R, Gotoh M, Tsuzuki T. Prognostic parameter for high risk prostate cancer patients at initial presentation Prostate. 2018.01; 78 (1): 11-16.

  105. Hirakawa A, Yonemori K, Kinoshita F, Kobayashi Y, Okuma HS, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Harris PJ, Takebe N. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. Cancer science. 2018.01; 109 (1): 207-214. ( PubMed, DOI )

  106. Kawase Y, Kawasaki M, Tanigaki T, Omori H, Hirata T, Okamoto S, Ota H, Kikuchi J, Okubo M, Kamiya H, Hirakawa A, Suzuki T, Matsuo H. Postocclusional hyperemia for fractional flow reserve after percutaneous coronary intervention JACC-Cardiovascular Interventions. 2017.12; 10 (12): e005674.

  107. Nomura S, Hirakawa A, Hamada C.. Sample size determination for the current strategy in oncology phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework. Journal of Biopharmaceutical Statistics. 2017.12; 28 (4): 589-611.

  108. Hashizume A, Katsuno M, Suzuki K, Hirakawa A, Hijikata Y, Yamada S, Inagaki T, Banno H, Sobue G. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study. Journal of neurology, neurosurgery, and psychiatry. 2017.12; 88 (12): 1026-1032. ( PubMed, DOI )

  109. Chantarojanasiri T, Hirooka Y, Kawashima H, Ohno E, Kuwahara T, Yamamura T, Funasaka K, Nakamura M, Miyahara R, Ishigami M, Watanabe O, Hashimoto S, Hirakawa A, Ratanachu-ek T, Goto H. Endoscopic ultrasound in diagnosis of solid pancreatic lesions: Elastography or contrast-enhanced harmonic alone versus the combination Endoscopy International Open. 2017.11; 5 (11): e1136-e1143.

  110. Ozeki N, Kawaguchi K, Fukui T, Fukumoto K, Nakamura S, Hakiri S, Kato T, Hirakawa A, Okasaka T, Yokoi K. The diffusing capacity of the lung for carbon monoxide is associated with the histopathological aggressiveness of lung adenocarcinoma European Journal of Cardio-Thoracic Surgery. 2017.11; 52 (5): 969-974.

  111. Yokoi A, Yoshioka Y, Hirakawa A, Yamamoto Y, Ishikawa M, Ikeda S, Kato T, Niimi K, Kajiyama H, Kikkawa F, Ochiya T. A combination of circulating miRNAs for the early detection of ovarian cancer Oncotarget. 2017.10; 8 (52): 89811-89823.

  112. Miyamoto K, Ohkawara B, Ito M, Masuda A, Hirakawa A, Sakai T, Hiraiwa H, Hamada T, Ishiguro N, Ohno K. Fluoxetine ameliorates cartilage degradation in osteoarthritis by inhibiting Wnt/β-catenin signaling PLoS One. 2017.09; 12 (9): e0184388.

  113. Shimizu S, Yamamoto T, Nakayama S, Hirakawa A, Kuwatsuka Y, Funahashi Y, Matsukawa Y, Takanari K, Toriyama K, Kamei Y, Narimoto K, Yamanishi T, Ishizuka O, Mizuno M, Gotoh M. Design of a single-arm clinical trial of regenerative therapy by periurethral injection of adipose-derived regenerative cells for male stress urinary incontinence in Japan: the ADRESU study protocol BMC Urology. 2017.09; 17 (1): 89.

  114. Kato T, Tamaki M, Tsunekawa T, Motoji Y, Hirakawa A, Okawa Y, Tomita S. Health-Related Quality of Life Prospectively Evaluated by the 8-item Short Form After Endovascular Repair Versus Open Surgery for Abdominal Aortic Aneurysms Heart Vessel. 2017.08; 32 (8): 960-968.

  115. Shimura M, Gosho M, Hirakawa A.. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data. Statistics in Medicine. 2017.06; 36 (13): 2067-2080.

  116. Sakamoto Y, Okamoto S, Shimizu K, Araki Y, Hirakawa A, Wakabayashi T. Hands-on simulation versus traditional video-learning in teaching microsurgery technique Neurologia Medico-Chirurgica. 2017.05; 57 (5): 238-245.

  117. Kato T, Tsunekawa T, Motoji Y, Hirakawa A, Okawa Y, Tomita S. The side-to-side fashion for individual distal coronary anastomosis using venous conduit Heart and Vessels. 2017.04; 32 (4): 385-389.

  118. Nakanishi K, Sato Y, Mizutani Y, Ito M, Hirakawa A, Higashi Y. Rat umbilical cord blood cells attenuate hypoxic-ischemic brain injury in neonatal rats Scientific Reports. 2017.03;

  119. Imai K, Kotani T, Tsuda H, Nakano T, Hirakawa A, Kikkawa F. A Novel Approach to Detecting Postpartum Hemorrhage Using Contrast-Enhanced Ultrasound Ultrasound in medicine and biology. 2017.03; 43 (3): 615-620.

  120. Hirakawa A, Kinoshita F. An Analysis of Japanese Patients Enrolled in Multiregional Clinical Trials in Oncology. Therapeutic innovation & regulatory science. 2017.03; 51 (2): 207-211. ( PubMed, DOI )

  121. 谷垣 徹, 川瀬 世史明, 平川 晃弘, 岡本 修一, 大森 寛行, 平田 哲夫, 菊地 淳, 太田 秀彰, 三宅 泰次, 川村 一太, 大久保 宗則, 松尾 仁司. 計算による冠血流予備量比の診断性能の比較 三次元定量的冠動脈造影と冠動脈CT血管造影の比較(Comparison of Diagnostic Performance of Computed Fractional Flow Reserve: 3-Dimentional Quantitative Coronary Angiography versus Coronary Computed Tomography Angiography) 日本循環器学会学術集会抄録集. 2017.03; 81回 OJ-134. ( ichushi )

  122. Miyauchi R, Itoh Y, Kawamura M, Hirakawa A, Shibata K, Kajiyama H, Nakahara R, Kubota S, Ito J, Okada T, Kikkawa F, Naganawa S. Postoperative chemoradiation therapy using high dose cisplatin and fluorouracil for high- and intermediate-risk uterine cervical cancer Nagoya Journal of Medical Science. 2017.02; 79 (2): 211-220.

  123. Yamasaki S, Hirakawa A, Aoki J, Uchida N, Fukuda T, Ogawa H, Ohashi K, Kondo T, Eto T, Kanamori H, Okumura H, Iwato K, Ichinohe T, Kanda J, Onizuka M, Kuwatsuka Y, Yanada M, Atsuta Y, Takami A, Yano S. Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia Annals of Hematology. 2017.02; 96 (2): 289-297.

  124. Asano J, Hirakawa A (co-first author). Assessing the prediction accuracy of a cure model for censored survival data with long-term survivors: application to breast cancer data. Journal of Biopharmaceutical Statistics. 2017.02; 27 (6): 918-932.

  125. Gosho M, Maruo K, Tada K, Hirakawa A.. Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems. European Journal of Clinical Pharmacology. 2017.01; 73 (6): 779-786.

  126. Sawamura A, Okumura T, Hirakawa A, Ito M, Ozaki Y, Ohte N, Amano T, Murohara T; CHANGE PUMP Investigators. Early Prediction Model for Successful Bridge to Recovery in Patients With Fulminant Myocarditis Supported With Percutaneous Venoarterial Extracorporeal Membrane Oxygenation - Insights From the CHANGE PUMP Study Circulation Journal. 2017; 82 (3): 699-707.

  127. Yamada S, Hashizume A, Hijikata Y, Inagaki T, Suzuki K, Kondo N, Kawai K, Noda S, Nakanishi H, Banno H, Hirakawa A, Koike H, Halievski K, Jordan CL, Katsuno M, Sobue G. Decreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular Atrophy PLoS One. 2016.12; 11 (12): e0168846.

  128. Fukui T, Fukumoto K, Okasaka T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N, Hirakawa A, Tateyama H, Yokoi K. Prognostic impact of tumour size in completely resected thymic epithelial tumours European Journal of Cardio-Thoracic Surgery. 2016.12; 50 (6): 1068-1074.

  129. Yamada S, Fujii T, Hirakawa A, Kanda M, Sugimoto H, Kodera Y. Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer Langenbeck's Archives of Surgery. 2016.12; 401 (8): 143-1152.

  130. Yonemori K, Hirakawa A (co-first author), Kawachi A, Kinoshita F, Ohkuma H, Nishikawa T, Kenji T, Fujiwara Y, Takebe N. . Drug induced Interstitial Lung Disease in Oncology Phase I Trials. Cancer Science. 2016.12; 107 (12): 1830-1836.

  131. Gosho M, Maruo K, Ishii R, Hirakawa A. Analysis of an incomplete longitudinal composite variable using a marginalized random effects model and multiple imputation. Statistical Methods in Medical Research. 2016.11; 27 (7): 2200-2215.

  132. Hirakawa A, Sato H, Gosho M.. Effect of design specifications in dose-finding trials for combination therapies in oncology. Pharmaceutical Statistics. 2016.11; 15 (6): 531-540.

  133. Sato H, Hirakawa A (co-first author), Hamada C. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials. Statistics in Medicine. 2016.10; 35 (23): 4093-4109.

  134. Atsuta Y, Hirakawa A, Nakasone H, Kurosawa S, Oshima K, Sakai R, Ohashi K, Takahashi S, Mori T, Ozawa Y, Fukuda T, Kanamori H, Morishima Y, Kato K, Yabe H, Sakamaki H, Taniguchi S, Yamashita T. Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation Biology of Blood and Marrow Transplantation. 2016.09; 22 (9): 1702-1709.

  135. Harano K, Yonemori K, Hirakawa A. The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study Breast Cancer. 2016.09; 23 (5): 797-806.

  136. Okuma H, Koizumi F, Hirakawa A, Nakatochi M, Komori O, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies British Journal of Cancer. 2016.08; 115 (4): 411-419.

  137. Watanabe H, Atsuta N, Hirakawa A (co-first author), Nakamura R, Nakatochi M, Ishigaki S, Iida A, Ikegawa S, Kubo M, Yokoi D, Watanabe H, Ito M, Katsuno M, Izumi Y, Morita M, Kanai K, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Kawata A, Aoki M, Tsuji S, Nakashima K, Kaji R, Sobue G. A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN Journal of Neurology, Neurosurgery, and Psychiatry. 2016.08; 87 (8): 851-858.

  138. Shimada K, Shimada S, Sugimoto K, Nakatochi M, Suguro M, Hirakawa A, Hocking TD, Takeuchi I, Tokunaga T, Takagi Y, Sakamoto A, Aoki T, Naoe T, Nakamura S, Hayakawa F, Seto M, Tomita A, Kiyoi H. Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma Leukemia. 2016.07; 30 (7): 1568-1579.

  139. Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, Inagaki T, Iida M, Noda S, Nakanishi H, Banno H, Mano T, Hirakawa A, Adachi H, Watanabe H, Yamamoto M, Sobue G. Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy Annals of Clinical and Translational Neurology. 2016.06; 23 (3): 537-546.

  140. Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group Gynecologic Oncology. 2016.06; 141 (3): 447-453.

  141. Yokoi D, Atsuta N, Watanabe H, Nakamura R, Hirakawa A, Ito M, Watanabe H, Katsuno M, Izumi Y, Morita M, Taniguchi A, Oda M, Abe K, Mizoguchi K, Kano O, Kuwabara S, Kaji R, Sobue G; JaCALS. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis Journal of Neurology. 2016.06; 263 (6): 1129-1136.

  142. Nagata T, Sobajima H, Ohashi N, Hirakawa A, Katsuno T, Yasuda Y, Matsuo S, Tsuboi N, Maruyama S. Association between 24h Urinary Sodium and Potassium Excretion and Estimated Glomerular Filtration Rate (eGFR) Decline or Death in Patients with Diabetes Mellitus and eGFR More than 30 ml/min/1.73m2 PLoS ONE. 2016.05; 11 (5): e0152306.

  143. Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Takahashi N, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. Risk factors for developing skeletal-related events in breast cancer patients with bone metastases undergoing treatment with bone-modifying agents Oncologist. 2016.04; 21 (4): 508-513.

  144. Fukui T, Fukumoto K, Okasaka T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N, Hirakawa A, Tateyama H, Yokoi K. Clinical evaluation of a new tumour-node-metastasis staging system for thymic malignancies proposed by the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and the International Thymic Malignancy Interest Group European Journal of Cardio-Thoracic Surgery. 2016.02; 49 (2): 575-579.

  145. Imai K, Kotani T, Tsuda H, Mano Y, Nakano T, Ushida T, Li H, Miki R, Sumigama S, Iwase A, Hirakawa A, Ohno K, Toyokuni S, Takeuchi H, Mizuno T, Suzumura A, Kikkawa F. Neuroprotective potential of molecular hydrogen against perinatal brain injury via suppression of activated microglia Free Radical Biology & Medicine. 2016.02; 91 154-163.

  146. Matsukawa Y, Takai S, Funahashi Y, Kato M, Yamamoto T, Hirakawa A, Gotoh M. The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia Urology. 2016.02; 88 149-154.

  147. Kato M, Tsuzuki T, Kimura K, Hirakawa A, Kinoshita F, Sassa N, Ishida R, Fukatsu A, Kimura T, Funahashi Y, Matsukawa Y, Hattori R, Gotoh M. The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation Modern Pathology. 2016.02; 29 (2): 166-173.

  148. Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group International Journal of Clinical Oncology. 2016.02; 21 168-176.

  149. Hirakawa A, Sato H. . Authors' Reply: Response to Letter to the Editor by Drs Riviere et al. Statistics in Medicine. 2016.02; 35 (3): 479-480.

  150. Tsuda H, Hirakawa A, Kotani T, Sumigama S, Mano Y, Nakano T, Imai K, Kawabata I, Takahashi Y, Iwagaki S, Kikkawa F. Risk assessment for neonatal RDS/TTN using gestational age and the amniotic lamellar body count in twin pregnancies Clinica Chimica Acta. 2015.12; 7 (451): 301-304.

  151. Nakano T, Kotani T, Mano Y, Tsuda H, Imai K, Ushida T, Li H, Miki R, Sumigama S, Sato Y, Iwase A, Hirakawa A, Asai M, Toyokuni S, Kikkawa F. Maternal molecular hydrogen administration on lipopolysaccharide-induced mouse fetal brain injury Journal of Clinical Biochemistry and Nutrition. 2015.11; 57 (3): 178-182.

  152. Suzuki N, Takedani H, Hirakawa A, Ushijima Y, Matsushita T. The features of clearance in recombinant factor IX (BeneFIX®) Haemophilia. 2015.09; 21 (5): 702-707.

  153. Gosho M, Hirakawa A, Maruo K, Noma H, Sato Y.. Comparison of bias-corrected covariance estimators for MMRM analysis in longitudinal data with dropouts. Statistical Method in Medical Research. 2015.08; 26 (5): 2389-2406.

  154. Nakamura S, Fukui T, Kawaguchi K, Fukumoto K, Hirakawa A, Yokoi K. Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma? Lung Cancer. 2015.07; 89 (1): 38-42.

  155. Hashizume A, Katsuno M, Suzuki K, Banno H, Suga N, Mano T, Araki A, Hijikata Y, Grunseich C, Kokkinis A, Hirakawa A, Watanabe H, Yamamoto M, Fischbeck KH, Sobue G. A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study Neuromuscular Disorders. 2015.07; 25 (7): 554-562.

  156. Kakurai Y, Hirakawa A, Hamada C.. A dose-finding method based on multiple dosing in two-agent combination phase I trials Journal of Biopharmaceutical Statistics. 2015.07; 25 (5): 1065-1076.

  157. Kato T, Iwano S, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, Fukumoto K, Nakamura S, Hirakawa A, Yokoi K. The contact length between the tumor contour and the lung on computed tomography is a risk factor for pleural recurrence after complete resection of thymoma General Thoracic and Cardiovascular Surgery. 2015.06; 63 (6): 343-348.

  158. Watanabe H, Atsuta N, Nakamura R, Hirakawa A (co-first author), Watanabe H, Ito M, Senda J, Katsuno M, Izumi Y, Morita M, Tomiyama H, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Aoki M, Tsuji S, Nakano I, Kaji R, Sobue G. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2015.06; 16 (3-4): 230-236.

  159. Kaneko S, Hirakawa A, Hamada C. . Enhancing the Lasso approach for developing a survival prediction model based on gene expression data. Computational and Mathematical Methods in Medicine. 2015.06; 2015 (259474):

  160. Okada N, Tajima K, Takami Y, Kato W, Kei F, Hibino M, Munakata H, Sakai Y, Hirakawa A, Usui A.. Valve selection for the aortic position in dialysis patients. The Annals of Thoracic Surgery. 2015.05; 99 (5): 1524-1531.

  161. Hirakawa A, Wages NA, Sato H, Matsui S.. A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies. Statistics in Medicine. 2015.05; 34 (24): 3194-3213.

  162. Hirakawa A and Matsui S.. Operating characteristics of restrictions on skipping dose level for adaptive dose-finding method in two-agent phase I trials. Japanese Journal of Biometrics. 2015.04; 36 (1): 1-12.

  163. Hattori T, Sato Y, Kondo T, Ichinohashi Y, Sugiyama Y, Yamamoto M, Kotani T, Hirata H, Hirakawa A, Suzuki S, Tsuji M, Ikeda T, Nakanishi K, Kojima S, Blomgren K, Hayakawa M. Administration of umbilical cord blood cells transiently decreased hypoxic-ischemic brain injury in neonatal rats Developmental Neuroscience. 2015.02; 37 (2): 95-104.

  164. Tsuda H, Kotani T, Sumigama S, Mano Y, Kawabata I, Takahashi Y, Iwagaki S, Hirakawa A, Kikkawa F. Amniotic lamellar body count: predicting and distinguishing neonatal respiratory complications in twin pregnancies Clinica Chimica Acta. 2015.02; 441 (20): 75-78.

  165. Kataoka Y, Nishida S, Hirakawa A, Oiso Y, Arima H. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus Endocrine Journal. 2015; 62 (2): 195-200.

  166. Ozeki N, Iwano S, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, Fukumoto K, Nakamura S, Hirakawa A, Yokoi K. Therapeutic surgery without a definitive diagnosis can be an option in selected patients with suspected lung cancer Interactive Cardiovascular and Thoracic Surgery. 2014.11; 19 (5): 830-837.

  167. Asano J, Hirakawa A, Hamada C. Assessing the prediction accuracy of cure in the Cox proportional hazards cure model: an application to breast cancer data. Pharmaceutical Statistics. 2014.07; 13 (6): 357-363.

  168. Yamada S, Hirakawa A. Reply to: appropriate statistical descriptions for evaluating the predictive role of epithelial-to-mesenchymal transition in patients with pancreatic cancer Surgery. 2014.05; 155 (5): 959-960.

  169. Goto M, Yamamoto T, Kato M, Majima T, Toriyama K, kamei Y, Matsukawa Y, Hirakawa A, Funahashi Y. Regenerative treatment of male stress urinary incontinence by periurethral injection of autologous adipose-derived regenerative cells: 1-year outcomes in 11 patients International Journal of Urology. 2014.05; 21 (3): 294-300.

  170. Hirakawa A, Matsui S.. Response to Letter to the Editor by Drs Wages et al. Statistics in Medicine. 2014.05; 33 (12): 2159-2160.

  171. Taniyama TK, Hashimoto K, Katsumata, N, Hirakawa A, Yonemori K, Yunokawa M,S himizu C,Tamura K, Ando M, Fujiwara Y. Can oncologists predict survival for patients with progressive disease after standard chemotherapies? Current Oncology. 2014.04; 21 (2): 84-90.

  172. Ozeki N, Fukui T, Taniguchi T, Usami N, Kawaguchi K, Ito S, Sakao Y, Mitsudomi T, Hirakawa A, Yokoi K. Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small cell lung cancer European Journal of Cardio-Thoracic Surgery. 2014.04; 45 (4): 687-692.

  173. Harano K, Hirakawa A, Kato T, Suzuki K, Watanabe S, Katsumata N. Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan Journal Gynecologic Oncology. 2014.04; 25 (2): 124-129.

  174. Asakawa T, Hirakawa A, Hamada C.. Bayesian model averaging continual reassessment method for bivariate binary efficacy and toxicity outcomes in phase I oncology trials. Journal of Biopharmaceutical Statistics. 2014.03; 24 (2): 310-325.

  175. Arima H, Wakabayashi T, Nagatani T, Fujii M, Hirakawa A, Murase T, Yambe Y, Yamada T, Yamakawa F, Yamamori I, Yamaguchi M, Oiso Y. Adipsia increases risk of death in patients with central diabetes insipidus Endocrine Journal. 2014; 61 (2): 143-148.

  176. Hirakawa A, Yonemori K, Kuwatsuka Y, Kodaira M, Yamamoto H, Yunokawa M, Hamada A, Shimizu C, Tamura K, Gemma A, Fujiwara Y. A descriptive analysis of post-chemotherapy development of interstitial lung disease using spontaneous reporting data in Japan. Current Drug Safety. 2014; 9 (3): 220-226.

  177. Nakamura S, Fukui T, Taniguchi T, Usami N, Kawaguchi K, Ishiguro F, Hirakawa A, Yokoi K. Prognostic impact of tumor size eliminating the ground glass opacity component: modified clinical T descriptors of the TNM classification of lung cancer Journal of Thoracic Oncology. 2013.12; 8 (12): 1551-1557.

  178. Nakamura R, Atsuta N, Watanabe H, Hirakawa A, Watanabe H, Ito M, Senda J, Katsuno M, Tanaka F, Izumi Y, Morita M, Ogaki K, Taniguchi A, Aiba I, Mizoguchi K, Okamoto K, Hasegawa K, Aoki M, Kawata A, Abe K, Oda M, Konagaya M, Imai T, Nakagawa M, Tsuji S, Kaji R, Nakano I, Sobue G. Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients Journal of Neurology, Neurosurgery, and Psychiatry. 2013.12; 84 (12): 1365-1371.

  179. Hirano K, Ohgomori T, Kobayashi K, Tanaka F, Matsumoto T, Natori T, Matsuyama Y, Uchimura K, Sakamoto K, Takeuchi H, Hirakawa A, Suzumura A, Sobue G, Ishiguro N, Imagama S, Kadomatsu K. Ablation of keratan sulfate accelerates early phase pathogenesis of ALS PLoS ONE. 2013.06; 25 (8): e66969.

  180. Sato Y, Kawataki M, Hirakawa A, Kato T, Itani T, Hayakawa M. The diameter of the inferior vena cava provides a noninvasive way of calculating central venous pressure in neonates Acta Paediatrica. 2013.06; 102 (6): e241-e246.

  181. Hirakawa A, Hamada C, Matsui S.. A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials. Statistics in Medicine. 2013.05; 32 (26): 4515-4525.

  182. Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, Hirakawa A, Takeuchi H, Suzumura A, Ishiguro N, Kadomatsu K. Minocycline selectively inhibits M1 polarization of microglia Cell Death & Disease. 2013.03; 7 (4): e525.

  183. Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer International Journal of Clinical Oncology. 2013.02; 18 (1): 132-138.

  184. Asano J, Hirakawa A, Hamada C, Yonemori K, Hirata T, Shimizu C, Tamura K, Fujiwara Y. Use of Cox’s cure model to establish clinical determinants of long-term disease-free survival in breast cancer patients treated with neoadjuvant chemotherapy International Journal of Breast Cancer. 2013;

  185. Asano J, Hirakawa A, Hamada C. . A stepwise variable selection for a Cox proportional hazards cure model with application to breast cancer data. Japanese Journal of Biometrics,. 2013; 34 (1): 21-34.

  186. Kojima Y, Hashimoto K, Ando M, Hirakawa A, Yonemori K, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Hosono A, Makimoto A, Fujiwara Y. Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy Journal of Cancer Research and Clinical Oncology. 2012.07; 138 (7): 1249-1257.

  187. Kaneko S, Hirakawa A, Hamada C.. Gene selection using a high-dimensional regression model with microarrays with cancer prognostic studies. Cancer Informatics. 2012.07; 11 29-39.

  188. Hirakawa A.. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials. Statistics in Medicine. 2012.03; 31 (6): 516-532.

  189. Hirakawa A, Hamada C, Yoshimura I.. Sample size calculation through the incorporation of heteroscedasticity and dependence for a penalized t-statistic in microarray experiments. Journal of Biopharmaceutical Statistics. 2012.01; 22 (2): 260-275.

  190. Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, Ryushima Y, Makino Y, Yokote N, Fujiwara Y, Saito Y, Yamamoto H. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer Biological & Pharmaceutical Bulletin. 2012; 35 (5): 717-724.

  191. Hashimoto K, Sasajima Y, Ando M, Yonemori K, Hirakawa A, Furuta K, Tsuda H, Fujiwara Y. Immunohistochemical profile for unknown primary adenocarcinoma PLoS ONE. 2012; 7 (1): e31181.

  192. Yonemori K, Hirakawa A, Ryushima Y, Saito M, Yamamotoro H, Hirata T, Ando M, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Yamamoto H, Fujiwara Y. An analysis of guidance for proper usage documents for oncology drugs in Japan Pharmaceutical Medicine. 2012; 26 165-170.

  193. Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Yasuhiro F. Content analysis of oncology-related pharmaceutical advertising in a peer-reviewed medical journal PLoS ONE. 2012; 7 (8): e44393.

  194. Hashimoto K, Yonemori K, Katsumata N, Hirakawa A, Hirata T, Yamamoto H, Shimizu C, Tamura K, Ando M, Fujiwara Y. Use of squamous cell carcinoma antigen as biomarker of chemotherapy response in patients with metastatic cervical carcinoma European Journal of Obstetrics & Gynecology and Reproductive Biology. 2011.12; 159 (2): 394-398.

  195. Hirata T, Yonemori K, Hirakawa A, Shimizu C, Tamura K, Ando M, Katsumata N, Tanimoto M, Fujiwara Y. Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients European Respiratory Journal. 2011.12; 38 (6): 1425-1430.

  196. Yonemori K, Tsuta K, Ando M, Hirakawa A, Hatanaka Y, Matsuno Y, Chuman H, Yamazaki N, Fujiwara Y, Hasegawa T. Contrasting prognostic implications of platelet-derived growth factor receptor-beta and vascular endothelial growth factor receptor-2 in patients with angiosarcoma Annals of Surgical Oncology. 2011.10; 18 (10): 2841-2850.

  197. Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. The notorious “drug lag” for oncology in Japan Investigational New Drugs. 2011.08; 29 (4): 706-712.

  198. Hirakawa A, Hamada C, Yoshimura I. Sample size calculation for a regularized t-statistic in microarray experiments. Statistics and Probability Letters. 2011.07; 81 (7): 870-875.

  199. Yonemori K, Hirakawa A, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. Compliance with good clinical practice in oncology registration trials in Japan Annals of Oncology. 2011.06; 22 (6): 1451-1456.

  200. Hashimoto K, Yonemori K, Shimizu C, Hirakawa A, Yamamoto H, Ono M, Hirata T, Kouno T, Tamura K, Katsumata N, Ando M, Fujiwara Y. A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer Medical Oncology. 2011.06; 28 (2): 434-440.

  201. Hirata T, Yonemori K, Ando M, Hirakawa A, Tsuda H, Hasegawa T, Chuman H, Namikawa K, Yamazaki N, Fujiwara Y. Efficacy of taxane regimens in patients with metastatic angiosarcoma European Journal of Dermatology. 2011.06; 21 (4): 539-545.

  202. Yonemori K, Hirakawa A, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. Do investigators show selection biases when enrolling patients in phase I oncology registration trials? Journal of Geriatric Oncology. 2011.01; 2 (1): 25-30.

  203. Hashimoto K, Yonemori K, Katsumata N, Shimizu C, Hirakawa A, Hirata T, Kouno T, Tamura K, Ando M, Fujiwara Y. Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy Annals of Oncology. 2010.11; 21 (11): 2195-2200.

  204. Ando Y, Hirakawa A. . Discussion of “Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations”. Statistics in Biopharmaceutical Research. 2010.11; 2 (4): 462-465.

  205. Yonemori K, Hirakawa A, Komiyama N, Kouno T, Ando M, Fujiwara Y, Urano T, Akagawa H, Maruyama H, Toyoshima S. Participation of elderly patients in registration trials for oncology drug applications in Japan Annals of Oncology. 2010.10; 21 (10): 2112-2118.

  206. Ando Y, Hirakawa A, Uyama Y.. Adaptive clinical trials for new drug applications in Japan. European Neuropsychopharmacology. 2010.10; 21 (2): 175-179.

  207. Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hirakawa A, Ono M, Kouno T, Katsumata N, Ando M, Tamura K, Hasegawa T, Kinoshita T, Fujiwara Y. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy Journal of Surgical Oncology. 2010.05; 101 (3): 222-227.

  208. Yonemori K, Kouno T, Ando M, Hirakawa A, Yamamoto H, Ono M, Hirata T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y. Influence of suboptimal treatment in patients with mediastinal primary non-seminomatous germ cell tumor Oncology. 2010; 78 (1): 34-39.

  209. Hirata T, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, Ando M, Katsumata N, Fujiwara Y. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer British Journal of Cancer. 2009.11; 101 (9): 1529-1536.

  210. Yonemori K, Ando M, Yunokawa M, Hirata T, Kouno T, Shimizu C, Tamura K, Katsumata N, Hirakawa A, Matsumoto K, Yamanaka Y, Arioka H, Fujiwara Y. Irinotecan plus carboplatin for patients with carcinoma of unknown primary site British Journal of Cancer. 2009.01; 100 (1): 50-55.

  211. Hirakawa A, Sato Y, Hamada C, Yoshimura I.. A new test statistic based on shrunken sample variance for identifying differentially expressed genes in small microarray experiments. Bioinformatics and Biology Insights. 2008.02; 29 (2): 145-156.

  212. Hirakawa A, Sato Y, Sozu T, Hamada C, Yoshimura I. Estimating the false discovery rate using mixed normal distribution for identifying differentially expressed genes in microarray data analysis. Cancer Informatics. 2007.02; 3 (6): 140-148.

▼display all

Books etc 【 display / non-display

  1. Daimon T, Hirakawa A, Matsui S. Dose-Finding Designs for Early Phase Cancer Clinical Trials. Springer, 2019

  2. Hirakawa A, Sato H, Daimon T, Matsui S. Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted. Springer, 2018

  3. Hirakawa A, Sato H. Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer, 2017

  4. Hirakawa A, Matsui S. Developments in Statistical Evaluation of Clinical Trials. Springer, 2014

  5. Daimon T, Hirakawa A, Matsui S. Design and Analysis of Clinical Trials for Predictive Medicine. CRC Press, 2014

Conference Activities & Talks 【 display / non-display

  1. Sato H, Sasaki M, Hirakawa A. Model calibration approaches for model uncertainty of dose-efficacy relationship in phase I trials for monotherapy of molecularly targeted agents.. 2022 WNAR Annual Meeting 2022.06.13

  2. Ikeda S, Kudo R, Yamashita, Y, Kubo T, Mori Y, Harada Y, Shirota H, Hayashi H, Kano M, Shimizu Y, Ishibashi E, Tateishi U, Hirakawa A, Akita H, Matsubara H, Nishihara H, Ishioka C, Sueoka-Aragane N, Muto M, Toyooka S. Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors. . Annual Meeting, American Society of Clinical Oncology 2022.06.05

  3. Arakawa A, Ozawa H, Hirakawa A, Sadachi R, Hoshina Y, Tomatsuri S, Saito Y, Ando R, Terashima K, Nakamura K, Ogawa C. A phase I trial of dual EZH 1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric, adolescent, and young adult patients with malignant solid tumors.. Annual Meeting, American Society of Clinical Oncology 2022.06.03

  4. Kojima Y, Shimizu T, Yonemori K, Koyama T, Matsui N, Kamikura M, Tomatsuri S, Sumiyoshi Okuma H, Shimoi T, Noguchi E, Sudo K, Hirakawa A, Sadachi S, Okita N, Nakamura K, Yamamoto N, Fujiwara Y.. A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra- rare cancer with a highly life-threatening unmet needs(NCCH1806/MK004). ESMO Congress 2021 2021.09.16

  5. Hasegawa K, Nishikawa T, Hirakawa A, Kawasaki M, Tomatsuri S, Nagasaka Y, Nakamura K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Yoshida H, Yonemori K. . Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE TRIAL, NCCH1615): A MULTICENTER, PHASE 2 CLINICAL TRIAL. . ESMO Congress 2021 2021.09.16

  6. Kudo R, Kubo T, Mori Y, Harada Y, Shirota H, Hayashi H, Kano M, Shimizu Y, Ishibashi E, Akita H, Matsubara H, Nishihara H, Ishioka C, Aragane N, Muto M, Toyooka S,1 Tateishi U, Hirakawa A, Miyake S, Ikeda S.. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial). ASCO 2021.06.04

  7. Kawai A, Nishikawa T, Kawasaki M, Tomatsuri S, Okamura N, Ogawa G, Hirakawa A, Shibata T, Nakamura K, Kakunaga S, Tamura K, Ando M, Ozaki T, Ueda T, Yonemori K. . Efficacy and Safety of Nivolumab Monotherapy in Patients with Unresectable Clear Cell Sarcoma and Alveolar Soft Part Sarcoma (OSCAR t rial, NCCH1510): A Multicenter, Phase 2 Clinical Trial OSCAR.. CTOS 2020 Annual Meeting 2020.11.18

  8. Asano J, Hirakawa A.. An Empirical Bayesian Basket Trial Design Accounting for Uncertainties of Homogeneity and Heterogeneity of Treatment Effect among Subpopulations. . ENAR 2020 Spring Meeting 2020.03.22

  9. Hirakawa A. An experience of data sharing utilization. 第16回DIA日本年会 2019.11.11

  10. Hirakawa A. Utility of Bayesian single-arm design in new drug application for rare cancers in Japan: application to basket trial data. 6th International Society of Biopharmaceutical Statistics 2019.08.26

  11. Hirakawa A. Single-pivotal basket trials for rare cancer development in Japan.. 2019 the Japanese Society of Medical Oncology Annual Meeting, 2019.07.19

  12. Hirakawa A. A clustering-based basket design. 3rd Pacific Rim Cancer Biostatistics Workshop 2019.06.27

  13. Hirakawa A. . A clustering-based basket design.. 3rd Pacific Rim Cancer Biostatistics Workshop 2019.06.27

  14. Hirakawa A, Sadachi R. A Basket Trial Design using Bayesian Model Averaging. ENAR 2019 Spring Meeting 2019.03.24

  15. Tanaka Y, Sozu T, Hirakawa A.. Dose-Finding Method for Molecularly Targeted Agents Incorporating the Relative Dose Intensity in Phase I Oncology Clinical Trials.. ENAR 2019 Spring Meeting 2019.03.24

  16. Sadachi R, Hirakawa A.. Heterogeneity Assessment of Treatment Effect among Subpopulations in Basket Trials. . ENAR 2019 Spring Meeting 2019.03.24

  17. Nishida Y, Hamada S, Kawai A, Kunisada T, Ogose A, Matsumoto Y, Ae K, Toguchida J, Ozaki T, Hirakawa A, Sakai T, Shimizu K, Kobayashi E, Gokita T, Okamoto T, Matsunobu, T. . Significant risk factors of local recurrence after surgery in extra-peritoneal desmoid-type fibromatosis: a multicenter study in Japan.. The CTOS 2018 Annual Meeting 2018.11.14

  18. Noda S, Yonemori K, Shirakawa N, Okuma H S, Shimizu T, Hirakawa A, Shibata T, Sukigara T, Okita N, Kawai A, Yamamoto N, Nakamura K, Mano H, Nishida T, Fujiwara Y. . MASTER KEY Project – a basket/umbrella trial for rare cancers in Japan. . ESMO 2018.10.19

  19. Hirakawa A. Adaptive Designs in Clinical Trials. ICPM 2018: 20th International Conference on Psychosomatic Medicine 2018.09.27

  20. Asano J, Hirakawa A.. An evaluation and modification of Simon's basket design in oncology. . International Society of Clinical Biostatistics 2018.08.26

  21. Noda S, Yonemori K, Shirakawa N, Okuma H S, Shimizu T, Hirakawa A, Shibata T, Sukigara T, Okita N, Kawai A, Yamamoto N, Nakamura K, Mano H, Nishida T, Fujiwara Y.. MASTER KEY Project – a basket/umbrella trial for rare cancers in Japan. . ASCO 2018.06.01

  22. Hirakawa A. Two-stage dose and zone finding method for two agent combination phase 1/2 trials. 2nd Pacific Rim Cancer Biostatistics Workshop 2017.10.12

  23. Hirakawa A. . Two-stage dose and zone finding method for two agent combination phase 1/2 trials.. Pacific Rim Cancer Biostatistics Workshop 2017.10.12

  24. Hirakawa A. Statistical Consideration for Novel Dose Escalation Methods in Phase 1 Oncology Trials. 2nd NCCH Workshop 2017.07.23

  25. Kakurai Y, Hirakawa A, Hamada C. . Dose individualization based on multiple gene mutations for molecularly targeted agents.. 日本計量生物学会年会 2017.03.16

  26. Hirakawa A, Kakurai Y, Kaneko S, Hamada C. Dose individualization based on multiple gene mutations for molecularly targeted agents. 37th International Society for Clinical Biostatistics 2016.08.21

  27. Hirata T, Kawase Y, Kikuchi J, Hirakawa A, Okamoto S, Omori H, Nakatani Y, Ota H, Saigusa T, Miyake T, Kawamura I, Okubo M, Tsuchiya K, Matsuo H.. The validation of the ischemic cut off of IFR and IFRa (During Hyperemia), to predict the ischemic threshold of FFR.. 第80回日本循環器学会学術集会 2016.03.18

  28. Yoshimi A, Yamada S, Kunimoto S, Aleksic B, Hirakawa A, Ohashi M, Matsumoto Y, Arioka Y, Oya-Ito T, Kushima I, Nakamura Y, Shiino T, Mori D, Maeda T, Tanaka S, Hamada S, Noma H, Yoshida M, Noda Y, Nagai T, Yamada K, Ozaki N.. The development of molecular diagnostic tool for schizophrenia using lymphoblastoid cell lines.. US HUPO 2016 Conference 2016.03.13

  29. Hirakawa A. A Data-Driven Clustering Method Using a Mixture Approach of Nonlinear Mixed-Effects Model for Longitudinal Functional Rating Scale in Amyotrophic Lateral Sclerosis Patients. East Asia Regional Biometric Conference 2015 2015.12.20

  30. Shimamura F, Hirakawa A, Hamada C.. Dose Finding Design for Two-Agent Combination Trials. . East Asia Regional Biometric Conference 2015 2015.12.20

  31. Kaneko S, Hirakawa A, Hamada C.. Establishing Individualized Treatment Rules Based on Bayesian Model Averaging Approach.. East Asia Regional Biometric Conference 2015 2015.12.20

  32. Sato H, Hirakawa A, Hamada C.. An Adaptive Dose-Finding Method Using a Change-Point Model for Molecularly Targeted Agents in Phase I Trials.. East Asia Regional Biometric Conference 2015 2015.12.20

  33. Shimoi T, Yonemori K, Hirakawa A, Kinoshita F, Bun S, Shimomura S, Kodaira M, Yunokawa M, Shimizu C, Fujiwara Y, Tamura K. . Is there a relationship between oncology drugs’ costs and efficacy? . European Society for Medical Oncology 2015.09.25

  34. Kawachi A, Yonemori K, Hirakawa A, Kinoshita F, Tamura K, Fujiwara Y, Takebe N. . Incidence and risk factors in interstitial lung disease in Cancer Therapy Evaluation Program phase I trials. . European Society for Medical Oncology 2015.09.25

  35. Shimura M, Gosho M, Hirakawa A.. A comparison of conditional bias-adjusted estimators of a treatment difference for continuous data in group sequential designs.. Royal Statistical Society 2015.09.07

  36. Asano J, Hirakawa A.. A novel C-statistic for evaluating prediction accuracy in a cure model for censored survival data with long-term survivors. . 36th Annual Conference of the International for Clinical Biostatistics 2015.08.23

  37. Hirakawa A. Dose-finding designs for combination therapies in oncology. 1st Pacific Rim Cancer Biostatistics Workshop 2015.08.14

  38. Hashimoto J, Koizumi F, Okuma H, Hirakawa A, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.. Integrative analysis of two prospective neoadjuvant studies with breast cancer patients and microarray analysis. 第13回日本臨床腫瘍学会学術集会 2015.07.16

  39. Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saiot T. . Optimal debulking surgery in patients with advanced uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.. 2015 Annual Meeting of the American Society of Clinical Oncology 2015.05.29

  40. Sato H, Hirakawa A, Hamada C.. Dose-finding approach based on efficacy and toxicity outcomes in phase I oncology trials for molecularly targeted agents.. The 2015 ENAR Spring Meet 2015.03.11

  41. Shimada K, Shimada S, Sugimoto K, Hayakawa F, Katayama M, Hirakawa A, Takagi Y, Nakamura S, Seto M, Naoe T, Tomita A, Kiyoi H.. Development and analysis of novel intravascular large B-cell lymphoma NOD/Shi-scid IL2Rγnull mouse xenograft model.. The 56th Annual Meeting of the American Society of Hematology 2014.12.06

  42. Yoshimi A, Aleksic B, Kunimoto S, Kushima I, Nakamura Y, Kimura H, Takasaki Y, Wang C, Xing J, Hirakawa A, Ikeda M, Iwata N, Ozaki N.. Transcriptome analysis of lymphoblastoid cell line from schizophrenia and bipolar disorder. . XXII World Congress of Psychiatric Genetics 2014.10.16

  43. Kato T, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, Hirakawa A, Iwano S, Yokoi K. . The contact length between the tumor contour and lung on computed tomography is a risk factor for pleural recurrence after complete resection of thymoma. . 28th Annual Meeting of the European Association for Cardio-Thoracic Surgery 2014.10.11

  44. Asano J, Hirakawa A, Hamada C.. Assessing the prediction accuracy of cure in the Cox proportional hazards cure model. . 35th International Society for Clinical Biostatistics 2014.08.24

  45. Nara E, Yunokawa M, Yonemori K, Doutani C, Shimizu K, Mimaki Y, Oomatsu N, Komatsu M, Hirakawa A, Shimizu C, Fujiwara Y, Tamura K.. Identifying the social support needs of young cancer patients in Japan. . European Society of Medical Oncology 2014.06.25

  46. Tanaka R, Yonemori K, Hirakawa A, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. . Risk factors for developing skeletal-related events associated with metastatic breast cancer patients receiving bone-modifying agents.. European Society of Medical Oncology 2014.06.25

  47. Okuma H, Koizumi F, Hirakawa A, Nakatochi M, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. . Integrative analysis of two prospective neoadjuvant studies with breast cancer patients and microarray analysis.. European Society of Medical Oncology 2014.06.25

  48. Yoshimi A, Kunimoto S, Yamada S, Aleksic B, Hirakawa A, Nagai T, Ozaki N. . Proteomic analysis of the lymphoblastoid cell line derived from Japanese schizophrenic patients. . 29th CINP World Congress of Neuropsychopharmacology 2014.06.22

  49. Usami N, Yokoi K, Murotani K, Hirakawa A, Tabata C, Soejima T, Kamikonya N, Tanaka F, Yamanaka T, Okada M, Hasegawa S, Nakano T. . Assessment of postoperative complications after the first all Japan multi-institutional trial of induction chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.. 15th World Conference on Lung Cancer 2013.10.27

  50. Nara E, Kodaira M, Hirakawa A, Noguchi E, Yamamoto H, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. . Risk factors of eribulin mesylate. 第11回日本臨床腫瘍学会学術集会 2013.08.29

  51. Asano J, Hirakawa A, Hamada C. . A stepwise variable selection for a Cox proportional hazards cure model. . 34th International Society for Clinical Biostatistics 2013.08.25

  52. Kakurai Y, Sano M, Hirakawa A, Hamada C.. A dose-finding approach based on cohort partitioning for combination of two agents in Phase I trials in oncology.. 34th International Society for Clinical Biostatistics 2013.08.25

  53. Nomura S, Hirakawa A, Hamada C.. Sample size calculation for confirming both PFS and OS simultaneously in cancer clinical trials.. 34th International Society for Clinical Biostatistics 2013.08.25

  54. Hirakawa A, Hamada C. . A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials. . XXVIth International Biometrics Conference 2012.08.26

  55. Yamada K, Hirakawa A, Hamada C. . Operating characteristics of the penalized Cox regression analysis in high-dimensional microarray data.. XXVIth International Biometrics Conference 2012.08.26

  56. Kaneko S, Hirakawa A, Hamada C.. Gene selection using a high-dimensional Cox model in microarray data analysis. . XXVIth International Biometrics Conference 2012.08.26

  57. Mano H, Hirakawa A, Hamada C.. Improvement of Trim and Fill method to adjust publication bias in meta-analysis using the clinical trial registration system. . XXVIth International Biometrics Conference 2012.08.26

  58. Atsumi J, Hirakawa A, Hamada C.. A new allocation method for balancing prognostic continuous and categorical variables in clinical trials.. XXVIth International Biometrics Conference 2012.08.26

  59. Asakawa T, Hirakawa A, Hamada C.. A dose-finding method using bayesian model averaging for bivariate binary efficacy and toxicity outcomes in phase I oncology trials.. XXVIth International Biometrics Conference 2012.08.26

  60. Asano J, Hirakawa A, Hamada C. . A stepwise variable selection for a Cox proportional hazards cure model. . XXVIth International Biometrics Conference 2012.08.26

  61. Hirakawa A, Hamada C. . An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials. . XXVIth International Biometrics Conference 2012.08.26

  62. Hirakawa A, Hamada C.. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.. 3rd East Asia Regional Biometric Conference 2012.02.02

  63. Asano J, Hirakawa A, Hamada C.. A stepwise variable selection for a cure model.. 3rd East Asia Regional Biometric Conference 2012.02.02

  64. Kaneko S, Yamada K, Hirakawa A, Hamada C.. Estimating the false positive rate in a high-dimensional regression model in cancer prognostic studies with microarrays. . 3rd East Asia Regional Biometric Conference 2012.02.02

  65. Hirakawa A, Kaneko S, Hamada C.. Gene selection using a high-dimensional Cox model in microarray data analysis. . Pacific Symposium on Biocomputing 2012.01.03

  66. Kaneko S, Hirakawa A, Hamada C.. Gene selection using a high-dimensional Cox model in microarray data analysis. 日本バイオインフォマティクス学会 2011.11.08

  67. Hirakawa A, Hamada C.. Sample size calculation for a regularized t-statistic in microarray experiments. 日本バイオインフォマティクス学会 2011.11.08

  68. Yonemori K, Hirakawa A, Ryushima Y, Saito M, Yamamoto H, Hirata T, Ando M, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Yamamoto H, Fujiwara Y.. Content analysis of “the guidance for proper usage” that are distributed to medical oncologists for promoting oncology pharmaceutical safety. . European Multidisciplinary Cancer Congress 2011.09.23

  69. Yamamoto H, Tamura K, Tsuda H, Kobayashi T, Hirakawa A, Shimizu C, Kinoshita T, Yunokawa M, Koizumi F, Masutomi K, Yonemori K, Ando M, Katsumata N, Fujiwara Y.. Nucleostemin as a predictive marker of pathologic complete response in neoadjuvant chemotherapy for breast cancer: a new biomarker of cancer stem cell and promoter of cell proliferation and tumorigenicity.. 第9回 日本臨床腫瘍学会学術集会 2011.07.21

  70. Hashimoto K, Sasajima Y, Ando M, Yonemori K, Hirakawa A, Kodaira M, Tomomatsu J, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Tsuda H, Fujiwara Y. . Molecular profiling (MP) as a possible prognostic marker for patients with cancer of unknown primary (CUP) treated using platinum doublet (PD) chemotherapy.. 第9回 日本臨床腫瘍学会学術集会 2011.07.21

  71. Harano K, Kojima Y, Hashimoto K, Ando M, Hirakawa A, Yonemori K, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Makimoto A, Fujiwara.. Clinical outcomes in adult and childhood rhabdomyosarcoma (RMS) treated with vincristine, d-actinomycin, and cyclophosphamide (VAC)/VAC-like chemotherapy. . Annual Meeting, American Society of Clinical Oncology 2011.06.03

  72. Hashimoto K, Sasajima M, Ando M, Yonemori K, Hirakawa A, Tsuda H, Fujiwara Y.. Molecular profiling as a possible prognostic marker for patients with cancer of unknown primary treated using platinum doublet chemotherapy. . Annual Meeting, American Society of Clinical Oncology 2011.06.03

  73. Asano J, Hirakawa A.. Covariate selection method in mixture cure model for survival data. . Eastern North American Region/International Biometric Society 2011.03.20

  74. Yamamoto H, Tamura K, Tsuda H, Kobayashi T, Hirakawa A, Shimizu C, Kinoshita, Yunokawa M, Koizumi F, Masutomi K, Yonemori K, Ando M, Katsumata N, Fujiwara Y. . Nucleostemin as a predictive marker of pathologic complete response in neoadjuvant chemotherapy for breast cancer: a new biomarker of cancer stem cell and promoter of cell proliferation and tumorigenicity. . 22nd International Congress on Anti Cancer Treatment 2011.02.01

  75. Yamamoto H, Yonemori K, Hirakawa A, Shimizu C, Ando M, Katsumata N, Tamura K, Kinoshita T, Tsuda H, Fujiwara Y.. Prognosis of elderly breast cancer patients with intermediate or high risk who received suboptimal adjuvant therapy. . European Society for Medical Oncology Congress 2010.10.08

  76. Hirakawa A, Hamada C, Yoshimura I.. A practical comparison of response-adaptive randomizations in clinical trials with binary responses.. 31th International Society of Clinical Biostatistics 2010.08.29

  77. Hirakawa A, Hamada C, Yoshimura I. . Sample size calculation through the incorporation of heteroscedasticity and dependence for a penalized t-statistic in microarray experiments. . 31th International Society of Clinical Biostatistics 2010.08.29

  78. Hirata T, Yonemori K, Ando M, Hirakawa A, Tsuda H, Hasegawa T, Chuman H, Namikawa K, Yamazaki N, Fujiwara Y. . Efficacy of taxane regimens in patients with metastatic angiosarcoma. . 21st International Congress on Anti-cancer Treatment 2010.02.01

  79. Yonemori K, Hirakawa A, Komiyama N, Kouno T, Ando M, Fujiwara Y, Urano T, Akagawa H, Maruyama H, Toyoshima S.. Participation of elderly patients in registered clinical trials for cancer drug applications in Japan. . The 10th Meeting of the International Society of Geriatric Oncology 2009.10.15

  80. Kotani N, Katsumata N, Yonemori K, Hirakawa A, Yamamoto H, Ono M, Hirata T, Yunokawa M, Kouno T, Shimizu C, Tamura K, Fujiwara Y. . Feasibility, efficacy and toxicity of carboplatin and paclitaxel as a first-line treatment in elderly patients with ovarian cancer. . The 10th Meeting of the International Society of Geriatric Oncology 2009.10.15

  81. Hashimoto K, Yonemori K, Shimizu C, Hirakawa A, Yamamoto H, Ono M, Hirata T, Kouno T, Tamura K, Katsumata N, Fujiwara Y. . Identification of clinical decision making factors in the treatment of geriatric patients with metastatic or recurrent breast cancer.. The 10th Meeting of the International Society of Geriatric Oncology 2009.10.15

  82. Hashimoto K, Yonemori K, Katsumata N, Hirakawa A, Shimizu C, Hirata T, Kouno T, Tamura K, Ando M, Fujiwara Y.. Prediction of progressive disease using tumor marker in breast cancer patients without target lesion in first-line chemotherapy.. ASCO Breast Cancer Symposium 2009.10.08

  83. Hirata T, Yonemori K, Hirakawa A, Kouno T, Shimizu C, Tamura K, Ando M, Katsumata N, Fujiwara Y.. A retrospective comparison of pleural progression free survival between systemic therapy alone and pleurodesis followed by preceding systemic therapy in breast cancer patients with malignant pleural effusion. . ASCO Breast Cancer Symposium 2009.10.08

  84. Hirakawa A, Hamada C, Yoshimura I. . Sample size calculation for a regularized t-statistic in microarray experiments.. 30th International Society of Clinical Biostatistics 2009.08.23

  85. Hirakawa A, Sato Y, Hamada C, Yoshimura I.. An adjusted test statistic based on shrunken sample variance for identifying differentially expressed genes in microarray experiments. . XX IVth International Biometric Conference 2008.07.13

  86. Hirakawa A, Sato Y, Hamada C, Yoshimura I.. A test statistic based on shrunken sample variance for identifying differentially expressed genes in microarray data analysis.. 1st East Asia Regional Biometrics Conference 2007.12.09

  87. Hirakawa A, Sato Y, Hamada C, Yoshimura I. . A statistical method to estimate sensitivity and specificity for identifying marker genes with microarray data. . 28th International Society of Clinical Biostatistics 2007.07.29

  88. Hirakawa A, Sato Y, Sozu T, Hamada C, Yoshimura I.. Estimating the false discovery rate using a normal mixture distribution with microarray data.. XX III International Biometric Conference 2006.06.16

  89. Sato Y, Ando H, Hirakawa A, Suganami H, Hamada C, Yoshimura I, Yoshida T, Yoshimura K. . Multiple imputation method for SNP typing data in linkage disequilibrium mapping of polygenic traits. . Joint Statistical Meetings 2005.08.07

▼display all